医学
减速器
食品药品监督管理局
循环系统
审议
重症监护医学
医疗急救
内科学
政治学
政治
工程类
土木工程
法学
作者
Giorgio A. Medranda,Rebecca Torguson,Ron Waksman
摘要
Abstract Refractory angina is considered a devastating condition with limited medical and therapeutic options. The Neovasc Reducer device, when implanted in the coronary sinus, is designed to alleviate anginal symptoms. However, the available clinical data are sparse. The US Food and Drug Administration (FDA) assembled the Circulatory Systems Devices Panel to discuss the Reducer's safety and effectiveness. Because of the coronavirus disease 2019 pandemic, this meeting was held virtually. In this manuscript, we detail the deliberation and discussion among the circulatory panel members, including their final vote.
科研通智能强力驱动
Strongly Powered by AbleSci AI